Disrupted organ growth leads to disease development. Hypertrophy underlies postnatal heart growth and is triggered after stress, but the molecular mechanisms involved in these processes are largely unknown. Here we show that cardiac activation of p38g and p38d increases during postnatal development and by hypertrophy-inducing stimuli. p38g/d promote cardiac hypertrophy by phosphorylating the mTORC1 and mTORC2 inhibitor DEPTOR, which leads to its degradation and mTOR activation. Hearts from mice lacking one or both kinases are below normal size, have high levels of DEPTOR, low activity of the mTOR pathway and reduced protein synthesis. The phenotype of p38g/d À / À mice is reverted by overactivation of mTOR with amino acids, shRNA-mediated knockdown of Deptor, or cardiomyocyte overexpression of active p38g and p38d. Moreover, in WT mice, heart weight is reduced by cardiac overexpression of DEPTOR. Our results demonstrate that p38g/d control heart growth by modulating mTOR pathway through DEPTOR phosphorylation and subsequent degradation.
C ardiac growth is tightly regulated to ensure that the heart reaches its appropriate size. Cardiomyocytes rapidly proliferate during fetal life, but soon after birth differentiated cardiomyocytes enter a postmitotic state and the ability to proliferate is lost. Postnatal cardiac growth is therefore mainly achieved through increases in cell size (physiological hypertrophy) associated with increased protein synthesis 1 together with the expansion of non-myocyte populations 2 . Hypertrophic growth is also the adaptive response of cardiomyocytes to stress stimuli, including cardiac pressure or volume overload, cytoskeletal abnormalities and intrinsic contractility defects. Although cardiomyocyte hypertrophy initially enhances cardiac output in stress situations, prolonged hypertrophy, known as pathological hypertrophy, is associated with an increased risk of morbidity and mortality due to cardiovascular diseases such as diastolic and systolic heart failure and arrhythmia 3 . Understanding the mechanism of cardiac growth thus has important clinical implications. The key unanswered questions are how cells perceive extracellular hypertrophic stimuli and convert them into intracellular signals, and how these signals lead to cardiac hypertrophy 4 .
Several studies identified mammalian TOR (mTOR) as a key regulator of cardiac hypertrophy; for example, the mTOR inhibitor rapamycin prevents heart-weight gain in an overload model of hypertrophy 5 and blocks cardiomyocyte size increases induced by AngII 6 and phenylephrine 7 , likely by inhibiting protein synthesis 7 . mTOR is a conserved serine/threonine kinase with a key regulatory function in cardiovascular physiology and pathology 8 . mTOR integrates signals from growth factors, nutrients and stresses to regulate multiple processes, including translation, cell cycle progression, autophagy and cell survival 9 . mTOR function is regulated by the formation of two multi-protein complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTORC1 is composed of the mTOR catalytic subunit and five associated proteins: Raptor, PRAS40, mLST8/GbL, DEPTOR and Tti1/Tel2. In mTORC2, the mTOR catalytic subunit is associated with six proteins: mLST8/GbL, DEPTOR, Tti1/Tel2 (in common with mTORC1) and Rictor, mSin1 and Protor 10 . The activities of the mTORC1 and mTORC2 pathways are regulated by the common inhibitory component DEPTOR 11 .
Stress-inducing stimuli in the heart activate several mitogenactivated protein kinases (MAPK), which are known to participate in hypertrophy, remodelling, contractility and heart failure 12, 13 . MAPKs are key regulators of cell stress responses, including cell proliferation, differentiation and apoptosis 14, 15 . The MAPK family consists of the extracellular signal-regulated protein kinases (ERK), the c-Jun NH2-terminal protein kinases (JNK) and the p38 MAP kinases 16 . Several studies have proposed that ERK cascade is involved in the hypertrophic response 17 . The p38 MAPKs are activated in response to proinflammatory cytokines, hormones and stress signals. Four p38 MAPK isoforms have been identified, and can be grouped into two subsets based on sequence homology, substrate specificity and sensitivity to chemical inhibitors: p38a and p38b, and p38g and p38d (ref. 15 ). MKK3 and MKK6, the kinases acting upstream of p38 MAPKs, appear to play a role in cardiac hypertrophy 18 , and susceptibility to cardiac hypertrophy is promoted by cardiacspecific overexpression of dominant-negative p38a (ref. 19 ). However, findings in mice lacking p38a in cardiomyocytes indicate that this effect is p38a independent 20 , whereas heart development requires endogenous p38b (ref. 21) . Although the p38g isoform is highly abundant in the heart 22 and p38d is also expressed in cardiomyocytes 23 , little is known about the role of these isoforms in cardiac hypertrophy 24 .
Here, we report that p38g and the closely related kinase p38d are activated by pathological and physiological hypertrophic stimuli and are required for cardiac physiological and pathological hypertrophy. Using p38g/d null mice, we show that p38g and p38d interact with and phosphorylate the inhibitory mTOR complex component DEPTOR, inducing its degradation and thus promoting cell growth.
Results p38c and p38d modulate postnatal cardiac hypertrophic growth. Stress stimuli in the heart activate several MAPKs, which have been implicated in mechanisms of cardiomyocyte hypertrophy and survival 13 . p38g is abundant in heart tissue, and the closely related isoform p38d is also well expressed 23 . Stress-induced hypertrophy appears to modulate the levels of both kinases 23 , but their function and activation in the heart remain unsolved. Analysis of wild-type (WT) mice showed that expression of both kinases increases during postnatal growth and that they become activated, p38g activity peaking on postnatal week 2 coinciding with the transition to hypertrophic growth 25 , and p38d activity peaking on postnatal week 6 (Fig. 1a) . To assess the role of p38g and p38d in cardiac growth, we used knockout mice lacking p38g, p38d or both kinases, confirming the deletion of these kinases in the heart by western blot ( Supplementary Fig. 1a ). Ventricular mass between postnatal weeks 4 and 11 was monitored relative to tibia length in WT mice and mice lacking one or both of the kinases. Ventricular mass was notably lower in p38g À / À , p38d À / À and p38g/d À / À mice (Fig. 1b) . Lower heart mass in the knockout animals correlated with the presence of cardiomyocytes of below-normal size, determined from cell cross-sectional area on histological sections, suggesting a defect in postnatal hypertrophic growth (Fig. 1c,d ). Similar analysis conducted at postnatal day 1 showed no differences between genotypes in heart or body size ( Supplementary Fig. 1b,c) , indicating that p38g/d kinases modulate hypertrophic heart growth in the postnatal period, and not in the fetus.
Echocardiography of 9-week-old mice revealed a thinner diastolic inter-ventricular septum (IVS) and telediastolic left ventricular posterior wall (LVPW;d) in p38g À / À , p38d À / À and p38g/d À / À mice than in age-matched WT mice, and this correlated with a below-normal corrected left ventricular mass (Fig. 1e) . However, the knockout models had normal systolic function, with no observed differences from WT in ejection fraction or fractional shortening (Fig. 1e) . Moreover, haematoxylin and eosin and Picrosirius red staining revealed no differences in fibrosis or cardiac morphology ( Supplementary Fig. 1d ,e).
p38c and p38d control pathological hypertrophy. The involvement of p38g and p38d in physiological postnatal hypertrophic heart growth prompted us to examine whether these kinases are activated by angiotensin (Ang) II, a stress stimulus that induces hypertrophy in the adult heart 26, 27 . AngII induced phosphorylation and activation of p38g and p38d kinases in the heart (Fig. 2a) . Osmotic minipump administration of AngII over 28 days increased systolic arterial pressure in WT and all the three knockout models ( Supplementary Fig. 2a ), but only WT mice showed above-baseline increases in LV mass and IVS thickness ( Fig. 2b and Supplementary Fig. 2b,c) . In WT mice, heart mass (measured as the ventricular-weight-to-tibia-length ratio) increased almost 2-fold after 28 days of AngII infusion, whereas p38g/d À / À mice showed no hypertrophic growth ( Fig. 2c and Supplementary Fig. 2d ). Analysis of heart sections showed that AngII increased cardiomyocyte cross-sectional area in WT mice by around 50%; in contrast, cardiomyocyte cross-sectional area in AngII-treated p38g/d À / À , p38g À / À and p38d À / À mice did not differ from that observed in salinetreated mice (Fig. 2d,e and Supplementary Fig. 2e ). AngII treatment did not affect ejection fraction in WT or single or double KO mice, indicating preserved systolic ventricular function ( Fig. 2f and Supplementary Fig. 2f ), and the extent of fibrosis was similar in all genotypes ( Supplementary Fig. 2g ).
Impaired mTOR activation in hearts of p38c or p38d null mice. The size of mammalian cells is controlled by the mTOR pathway 28 . To assess whether mTOR signalling is altered in mice lacking p38g and p38d ( Supplementary Fig. 3a) , we analysed heart protein extracts by immunoblot. We found that cardiac activation of mTORC1 and mTORC2 was impaired in p38g/d À / À , p38g À / À and p38d À / À mice, as assessed by the phosphorylation of the mTOR targets p70S6K, S6 and FOXO1/3a and by mTOR autophosphorylation on Ser 2481 (Fig. 3a, Supplementary  Fig. 3b,c) ; in contrast, no changes were detected in the expression or activation of p38a ( Supplementary Fig. 3d ). A major function of mTORC1 is the promotion of protein synthesis 8 , an essential driver of hypertrophic cardiomyocyte growth. Immunoblot analysis of translation initiation/elongation factors in the hearts of p38g/d À / À mice revealed weak phosphorylation of EIF4E, EIF4G and EIF4B and strong phosphorylation of EF2 (Fig. 3b) , indicating that cardiac protein synthesis is impaired in these mice. To confirm this finding, we injected puromycin into WT and p38g/d À / À mice 30 min before heart extraction and measured its incorporation into newly synthesized proteins 29 . p38g/d À / À hearts contained fewer puromycin-labelled peptides than WT hearts, indicating a lower rate of protein synthesis (Fig. 3c) . The p38g/d pathway thus appears to support growth induction in the heart by promoting the activation of mTOR-regulated protein synthesis.
p38c and p38d interact with mTOR through DEPTOR. We next investigated whether p38g/d isoforms interact with components of the mTOR complexes. Immunoblot analysis of immunoprecipitated p38g from mouse embryonic fibroblasts (MEFs) surprisingly detected co-immunoprecipitation of several components of both mTORC1 and mTORC2 (Fig. 4a) . To hone the search for specific interactions, we focused on mTOR and DEPTOR, components common to the mTORC1 and mTORC2 complexes. DEPTOR has an inhibitory action on the mTOR pathway and contains a PDZ domain 11 , which has the potential to interact with the C-terminal of p38g, as occurs with other PDZ-containing proteins 30, 31 . To test DEPTOR-p38g interaction, we transfected HEK-293 cells with HA-tagged p38g, Flag-tagged DEPTOR and myc-tagged mTOR, alone and in combination. p38g co-immunoprecipitated with DEPTOR regardless of whether the cells co-expressed mTOR (Fig. 4b) ; 
*** *** *** ** ** *** *** *** in contrast, p38g only co-immunoprecipitated with mTOR when it was expressed together with DEPTOR ( Fig. 4c) Fig. 4b ).
To determine whether DEPTOR also interacts with p38d, we transfected HEK-293 cells with Flag-DEPTOR and either HA-p38g or HA-p38d. Although both kinases co-immunoprecipitated with DEPTOR, the interaction with HA-p38g appeared to be stronger (Fig. 4d) . However in MEF, we detected co-immunoprecipitation of DEPTOR with p38d ( Supplementary Fig. 4a ). Moreover, in vitro analysis indicated direct interaction of p38g and p38d with DEPTOR ( Supplementary Fig. 4d) . Surprisingly neither the PDZ nor DEP domains are sufficient for this interaction, because while p38d interacted with whole DEPTOR, it did not bind the individual DEP or PDZ domains ( Supplementary Fig. 4c ). Moreover, HA-p38d co-immunoprecipitated with endogenous p38g, indicating that p38g and p38d form part of the same complex (Fig. 4e ).
p38c and p38d modulate DEPTOR protein levels. DEPTOR contains several potential MAPK phosphorylation sites (S/T-P), located outside the PDZ domain. An in vitro kinase assay showed p38g-mediated phosphorylation of DEPTOR at four residues (Ser145, Ser244, 265 and Ser293) and p38d-mediated phosphorylation at two (Ser265 and Thr321); no phosphorylation by p38a was detected (Fig. 5a , Supplementary Fig. 5a ). DEPTOR phosphorylation on (S/T-P) residues in live cells was confirmed by immunoprecipitation/immunoblot analysis of HEK-293 cells transfected with DEPTOR or DEPTOR (13xS/T-A) mutant together with constitutively active p38g or p38d mutants ( Fig. 5b) and was confirmed by mass spectrometry to selected peptides (Supplementary Table 1 and Supplementary Fig. 5a ,b). DEPTOR levels increase in response to serum deprivation, resulting in mTOR inhibition, whereas serum stimulation leads to phosphorylation-dependent degradation of DEPTOR and enhanced mTOR activity 11, 32 (e) DEPTOR phosphorylation mutants were expressed in HEK-293T alone or together with constitutively active p38g and p38d mutants. Fresh media without serum was added together with 10 mM cycloheximide (CHX) and cells collected at the times indicated. DEPTOR degradation was analysed by immunoblot. Supplementary Fig. 6a ), and the effect was stronger in cells co-transfected with both kinases (Fig. 5c) . Similar results were obtained for endogenous DEPTOR in HeLa cells (Fig. 5d , Supplementary Fig. 6b ). Moreover, the DEPTOR (13xS/T-A) mutant was not degraded, confirming that DEPTOR degradation was phosphorylation-dependent ( Supplementary Fig. 6c ). We next determined which phosphorylation sites in DEPTOR are necessary for its degradation by generating single-point DEPTOR mutants through the substitution of serine/threonine with alanine in codons 145, 244, 265, 293 or 321 (Supplementary Table 2 ). The protein half-life of two mutants (S293A and T321A) was extended to the same level as that of the mutated DEPTOR (13xS/T-A) mutant ( Fig. 5e and Supplementary Fig. 6d ), whereas a more moderate half-life extension was observed for S244A and S265A mutants ( Fig. 5e and Supplementary  Fig. 6d ). These data indicate that p38g-and p38d-mediated phosphorylation of key residues targets DEPTOR for degradation. DEPTOR is a substrate of SCF E3 ubiquitin ligase 33 , and DEPTOR poly-ubiquitination is dependant on DEPTOR phosphorylation 33 . Then we assayed whether phosphorylation in vitro of DEPTOR by p38g or p38d promote ubiquitination of DEPTOR. Our results indicate that DEPTOR presented higher ubiquitination after in vitro phosphorylation by p38g and p38d ( Supplementary Fig. 6e ). Moreover, we observed that in HEK293, active p38g or p38d significantly enhanced poly-ubiquitination of native DEPTOR but not the non-phosphorylatable DEPTOR (13xS/T-A) mutant (Supplementary Figs 6f and 7a).
To determine whether p38g is involved in DEPTOR degradation after serum stimulation, we first verified the activation of the kinase in this setting ( Supplementary Fig. 7b ). MEFs lacking p38g/d had above-normal levels of DEPTOR and were resistant to DEPTOR degradation after serum stimulation (Fig. 6a) . No changes were found in the mTOR complex components Raptor or Sin1 (Supplementary Fig. 7c ). The above-normal and serum-independent DEPTOR content in p38g/d À / À cells correlated with impaired mTOR activation, measured by below-normal phosphorylation of p70S6K and its target S6 ( Supplementary Fig. 7c) . Moreover, the serum-independent DEPTOR content in these cells correlated with increased binding to mTOR (Supplementary Fig. 7d ). Consistent with impaired mTOR pathway activation ( Supplementary Fig. 7e ), p38g/d À / À MEFs had lower protein synthesis activity and were smaller than WT counterparts (Fig. 6b,c) .
To confirm whether p38g/d isoforms trigger DEPTOR degradation through a posttranscriptional mechanism, we treated MEFs with the protein synthesis inhibitor cycloheximide (CHX). DEPTOR levels in WT MEFs declined after 12 h exposure to CHX, whereas high DEPTOR levels were sustained in p38g/d null MEFs after 24 h (Supplementary Fig. 7f ). Consistent with these results, DEPTOR levels in HeLa cells were reduced by expression of the constitutively active p38g and p38d mutants, and this effect was blocked by the proteasome inhibitor MG132 (ref. 34 ; Fig. 6d ). As expected, shRNA-mediated suppression of DEPTOR in WT cells resulted in greater mTOR activation, protein synthesis and in consequence increased cell size ( Supplementary Fig. 8a-c) . Interestingly, treatment with DEPTOR shRNA in p38g/d À / À cells restored WT mTOR activity, protein synthesis and cell size (Fig. 6e,f, Supplementary Fig. 8d ). These results thus suggest that p38g/d isoforms are key regulators of DEPTOR degradation by the proteasome, thereby promoting mTOR-dependent protein synthesis and cell growth.
p38c/d regulation of mTOR activity controls heart hypertrophy. To determine whether p38g and p38d interact with cardiac mTOR complexes in vivo, we immunoprecipitated p38g and p38d from heart extracts. The immunoprecipitates contained several mTORC1 and mTORC2 components, including DEPTOR (Fig. 7a,b Supplementary Fig. 9a,b) . Moreover, p38g immunoprecipitates contained p38d and vice versa, confirming that the two kinases form part of the same complex in vivo ( Supplementary Fig. 9c,d ). Further analysis in heart extracts of p38g À / À and p38d À / À mice revealed that each kinase is needed for the interaction of the other in the mTOR complexes ( Supplementary Fig. 9c ), providing a probable explanation for the shared phenotype of p38g and p38d null mice.
The control of heart size by p38g/d-induced DEPTOR degradation in cardiomyocytes predicts that hearts from p38g and p38d null mice will present higher protein levels of DEPTOR, and this was confirmed by immunoblot analysis of hearts from 9-week-old animals (Fig. 7c) . Interestingly, DEPTOR mRNA levels were below normal in p38g and p38d null hearts, indicating that the increased DEPTOR protein expression is not owing to higher DEPTOR transcription (Supplementary Fig. 9e) . Moreover, DEPTOR levels were strongly reduced from P1 to 2 weeks in WT hearts, a period in which the heart switches from proliferation to hypertrophic growth. This correlated with maximal activation of p38g and p38d, and with the activation of mTOR (Fig. 7d) . Moreover, DEPTOR phosphorylation and ubiquitination in WT mice were increased during this period, whereas phosphorylation and ubiquitination were reduced in p38g and p38d null mice (Fig. 7e) . In WT mice, angiotensin II, which activates p38g and p38d (Fig. 2a) , also correlated with DEPTOR degradation and mTOR activation (Fig. 7f) . These results suggest that p38g and p38d modulate heart growth in vivo by controlling DEPTOR degradation and in consequence mTOR activity.
To determine whether the impaired heart growth in the p38g/d À / À animals results from an autonomous effect on postnatal cardiomyocyte growth, we generated mice lacking p38d in striated muscle by crossing mice carrying loxP-flanked p38d with MCK Cre mice (p38d Mck À KO ), which reach peak Cre expression on postnatal day 10 (ref. 35) . The cardiac phenotype of mice lacking p38d specifically in striated muscle resembled that of p38d À / À mice, suggesting that p38d-mediated control of heart growth is cell autonomous (Fig. 7g-j and Supplementary  Fig. 10a ). To further confirm that the phenotype is cardiac specific, we treated p38g/d À / À mice with cardiac-specific adeno-associated viruses expressing p38g/d active mutants under the troponin T promoter (AAV-TnT-p38g/dact). Cardiac-specific expression of p38g/d-active mutant reduced DEPTOR levels in p38g/d À / À heart to the levels of WT mice and increased mTOR activation (Fig. 8a) . In consequence, reduction of heart growth was reverted in p38g/d À / À mice treated with AAV-TnT-p38g/dact and cardiomyocyte cross-sectional area increased to WT levels (Fig. 8b,c) .
To confirm whether p38-mediated modulation of the mTOR pathway is responsible for normal postnatal heart growth, we treated MCK-cre and p38d Mck-KO mice with the mTOR inhibitor rapamycin from weeks 4 to 9 after birth. Rapamycin treatment reduced the heart weight and cardiomyocyte size only in control mice (MCK-cre), equalizing with heart weight in p38d Mck-KO mice (Fig. 8e,f) . Moreover, echocardiographic studies showed that rapamycin reduced diastolic IVS, LVPW and LV mass in MCKCre mice but not p38d Mck-KO mice (Fig. 8g) , without betweengenotype differences in ejection fraction (Fig. 8g) . Thus the small hearts in p38d Mck-KO and p38g/d KO mice appear to result from the inhibition of mTOR activation in these mice.
To test whether decreased mTOR signalling could account for the weak heart growth in p38g/d À / À mice, we hyperactivated mTOR with aminoacids (aa) to restore heart growth in p38g/d KO mice. As expected, daily aa injection activated the mTOR pathway in p38g/d À / À hearts (Supplementary Fig. 10b ).
Compared with saline treatment, aa supplementation significantly increased heart size, LV mass and cardiomyocite cross-sectional area ( Supplementary Fig. 10c-f) . Consistently, cardiac-specific overexpression of DEPTOR in WT mice resulted in reduced mTOR activation and lower heart mass, correlating with the presence of cardiomyocytes of below-normal size, determined from cell cross-sectional area on histological sections (Fig. 9a-d) .
To confirm that decreased DEPTOR degradation in cardiomyocytes contributes to the phenotype of p38g/d KO mice, we used DEPTOR-targeted shRNA under the promoter of cardiac troponin T (AAV-TnT-shDEPTOR). Cardiac-specific reduction of DEPTOR expression in p38g/d À / À mice was confirmed by western blot and was sufficient to restore mTOR activation (Fig. 9e) . Furthermore, these animals showed re-established cardiac growth and increased cardiomyocyte cross-sectional area (Fig. 9f-h ). Moreover, a control, AAV-Tnt or AAV-TnTshDEPTOR did not affect cardiac growth in WT mice (Supplementary Figs 11 and 12) . These results confirm that reduction of heart growth observed in p38g/d À / À mice is driven by the accumulation of DEPTOR caused by the absence of DEPTOR phosphorylation and degradation. DEPTOR accumulation inhibits mTOR pathway and consequently growth.
Discussion
In this study, we provide evidence that two stress kinases, p38g and p38d, promote the activity of mTOR, a critical sensor of metabolic and nutrient stresses, by targeting the mTOR inhibitory partner DEPTOR for proteasome degradation. The finding that DEPTOR is a physiological p38g/d substrate is, to our knowledge, the first demonstration of DEPTOR interaction with a nonmTOR complex protein. Moreover, our results show that p38g or p38d are both able to phosphorylate DEPTOR and induce its subsequent proteasomal degradation, contrary to the proposal that DEPTOR phosphorylation was only mTOR dependent 11 . The p38g/d-mTOR signalling pathway controls protein synthesis and cell growth, and molecular and functional evidence indicates that this pathway plays an important physiological role in the regulation of ventricular cardiac hypertrophy. Our conclusion is supported by several lines of evidence: (1) mTOR activity is below-normal in hearts and cells from mice deficient in p38g and p38d; (2) low mTOR activation in cells lacking p38g and p38d leads to reduced cell size and protein synthesis; (3) p38g and p38d co-immunoprecipitate with mTORC1 and mTORC2 complexes; (4) p38g and p38d bind to DEPTOR; (5) DEPTOR is phosphorylated by p38g and p38d; (6) DEPTOR protein half-life is shortened by active p38g and p38d mutants, but extended by knockout of p38g and p38d; (7) DEPTOR levels are elevated in hearts lacking p38d or p38g/d; (8) reduction of DEPTOR levels correlates with p38g and p38d activation; (9) silencing of DEPTOR in cells lacking p38g and p38d increases their protein content and size; (10) rapamycin treatment in the postnatal period equalizes heart size in WT and KO animals; (11) mTOR activation by aa injection into p38g/d À / À mice results in heart growth; (12) cardiac-specific overexpression of active p38g/d reduces DEPTOR levels, increasing mTOR activity and cardiomyocyte growth; (13) cardiac overexpression of DEPTOR phenocopies the p38g/d À / À phenotype; (14) cardiac-specific silencing DEPTOR in p38g/d À / À mice increases their heart size and cardiomyocyte growth.
Despite the physiological and pathological importance of cellsize regulation, our understanding of the underlying mechanisms remains very limited. In the heart, the regulation of cell size is a key process that modulates the organ's response to external stimuli. Identifying molecular mechanisms through which hypertrophy can be suppressed without provoking circulatory insufficiency is a major challenge. Our data strongly indicate that lack of p38g and p38d reduces the capacity for cardiomyocyte growth without having functional implications: cardiac function remained normal in these mice even in the presence of AngIIinduced hypertrophy, and they showed no increase in fibrosis with respect to WT mice. Surprisingly, although mTOR is necessary for embryonic cardiovascular development and for the postnatal maintenance of cardiac function 8 , inhibition of mTOR as a result of the lack of p38g and p38d does not have a deleterious effect on heart physiology in basal condition. This is likely because p38g and p38d act through the mTOR modulator DEPTOR, so that the lack of p38g and p38d results only in partial inhibition of mTOR activity. This finding is of great interest because other models in which the heart is incapable of growing display signs of cardiac pathology such as cardiac dilation or heart failure 36, 37 . The fact that the modulation of these kinases results in reduced heart hypertrophy without obvious secondary effects makes p38g and p38d potential targets for therapeutic intervention. However, it would be interesting to further study whether modulation of these kinases could have functional implication after a stronger challenge such as myocardial infarction.
Our findings provide definition of the previously uncharacterized role of p38g and p38d in cardiac hypertrophy 38 , demonstrating that p38g and p38d are activated during postnatal growth and by stress stimuli in the heart. This activation correlates with DEPTOR phosphorylation, ubiquitination and degradation, modulating cardiac growth in tissue culture and animal models. Mice deficient in these kinases presented reduced DEPTOR phosphorylation and degradation, correlating with impaired postnatal and pathologically induced cardiac hypertrophy.
The finding that lack of just one of these kinases produces the defect is quite surprising because each normally compensates the loss of the other in other biological processes. The nonredundancy of these isoforms in the induction of cardiac hypertrophy is likely explained by their interaction in vivo. Both kinases cooperate in the binding to the mTOR complex and in the modulation of its activity through the phosphorylation and subsequent ubiquitination and proteasomal degradation of DEPTOR. Although p38g interacts with DEPTOR through the PDZ domain, the exact interaction between DEPTOR and p38d remains unclear. Moreover, our experiments with single-point mutants indicated that both kinases are needed to induce DEPTOR degradation. Lack of phosphorylation on S293 or T321, residues respectively phosphorylated by p38g and p38d, are sufficient to abolish DEPTOR degradation, indicating a requirement for cooperation between both kinases to induce DEPTOR degradation. Moreover, mTOR induces DEPTOR phosphorylation on other residues, which are also necessary for DEPTOR ubiquitination and degradation 11, 32, 33 . Additional studies will be needed to clarify how these kinases cooperate to phosphorylate DEPTOR and to determine whether p38 g and d act as a heterodimer. Moreover it would be interesting to study whether this mechanism acts in other tissues and in response to other stimuli.
Cell autonomous control of cell hypertrophy by p38g and p38d was validated by several independent approaches, including the use of mice lacking p38d in myocytes, and immortalized fibroblasts from p38g/d À / À mice. Furthermore, hearts from p38g/d null animals are able to grow after AAV-mediated cardiomyocyte overexpression of p38g and p38d, and AAV-mediated DEPTOR overexpression in WT hearts reduces cardiomyocyte size. Finally, reduction of DEPTOR levels in cardiomyocytes from p38g/d null animals increased heart growth to the level seen in WT mice, indicating that the phenotype found in p38g/d null animals is mediated by DEPTOR. Our results identify p38g and p38d signalling as a key regulator of mTOR activity, promoting protein synthesis and cell hypertrophy by phosphorylating the mTOR inhibitor DEPTOR and inducing its ubiquitination and degradation. p38g/d signalling through mTOR complexes is an important mediator of cardiac hypertrophy, and this pathway may also be important in other physiological processes mediated by mTOR, such as cancer and autophagy. These results reveal a new avenue in the control of mTOR activation and open a route to the development of new treatment strategies for disease. (Jackson Laboratory). To generate mice lacking p38d in striated muscle, p38d (B6.129-Mapk13tm1) mice were crossed with the FVB-Tg(Ckmm-cre)5Khn/J line on the C57BL/6J background (Jackson Laboratory). Genotype was confirmed by PCR analysis of genomic DNA. For signalling studies, animals were killed by cervical dislocation. For AngII experiments, 9-week-old male mice were treated with AngII (1 mg kg À 1 per minute, 28 days) via subcutaneously implanted mini-osmotic pumps (Alzet); saline was administered as a control. For rapamycin treatment, mice were daily injected intraperitoneally with rapamycin (LC Laboratories, R-5000) (2 mg kg À 1 per day) or vehicle (0.25% polyethylene glycol (Sigma), 0.25% Tween-20 (Sigma) in PBS); injections started at 4 weeks of age and continued until 9 weeks of age, when heart size was analysed by echocardiography and mice were killed. Amino acid (aa) supplementation was achieved by daily intraperitoneal injections, starting at the day of birth, of aa solution at a dose of 0.1 ml g À 1 body weight, with a maximal dose of 2 ml per day 39 . All aa were purchased from Sigma-Aldrich. The solution contained the following aa concentrations: 6.0 g l À 1 isoleucine, 12.0 g l À 1 leucine, 7.2 g l À 1 valine, and 6.04 g l À 1 arginine (pH 7.4; Sigma). PBS (pH 7.4) was used as a control. Four-week-old mice were intravenously injected with 1 Â 10 12 viral particles encoding human p38g and p38d active mutants or wild-type human Flag-DEPTOR under the TnT promoter. Hearts were harvested from 9-week-old mice. Day-old mice were intravenously injected with 0.5 Â 10 12 viral particles encoding wild-type human Flag-DEPTOR under the TnT promoter and hearts were harvested for analysis of DEPTOR phosphorylarion/ubiquitination at 2 weeks of age. To avoid DEPTOR degradation, mice were injected the proteasome inhibitor MG132 (Shelleckchem; 0.1 mg kg À 1 per day intraperitoneally) on the 2 days before harvesting the hearts. In the cardiac-specific DEPTOR silencing experiment, 1-day-old mice were intravenously injected with 0. Echocardiography. Mice were anaesthetized by inhalation of isoflurane and oxygen (1.25% and 98.75%, respectively), and echocardiography was performed with a 30-MHz transthoracic echocardiography probe. Images were obtained with the Vevo 2100 micro-ultrasound imaging system (VisualSonics, Toronto, Canada). Short-axis, long-axis, B-mode and two-dimensional M-mode views were obtained. In summary, scans were conducted by two experienced researchers blinded to the mouse genotype. Measurements of left parasternal long and short axes and M-mode (left parasternal short axis) images were obtained at a heart rate of 500-550 b.p.m. LV end-diastolic diameter (LVEDD), LV end-systolic diameter (LVESD) and wall thickness were measured from M-mode tracings, and the average of three consecutive cardiac cycles is reported. The LV fractional shortening percentage was calculated as ([LVEDD À LVESD]/LVEDD) Â 100 MRI of lung was performed with a 7-T Agilent scanner (Agilent, Santa Clara, CA, USA) equipped with a DD2 console and an actively shielded gradient set (205/120 insert of maximum 130 mT m À 1 gradient strength). For image acquisition, we used a combination of volume coil/surface coil coil to enhance signal-to-noise ratio formed by a 72-mm inner diameter quadrature birdcage TX coil (Rapid Biomedical GmBH, Germany) and an actively detuning 30-mm flexible customized surface RX coil (Neos Biotec, Pamplona, Spain). Following a tripilot gradient-echo image, a gradient-echo sequence without gating was used to acquire oblique coronal slices (one to two slices) and axial slices (7-10 slices covering the entire lung, 72-s acquisition time per slice) using the following parameters: TR/TE ¼ 6.7/2.2 ms, flip angle ¼ 10 degree, bandwidth ¼ 100 kHz, field of view ¼ 3 Â 3 cm, matrix ¼ 256 Â 128, slice thickness ¼ 1 mm (ref. 40) . From these images, interventricular septum and left ventricle posterior wall thicknesses and left ventricle corrected mass were determined; the short-axis M-mode quantification was chosen as the most representative. Function was estimated from the ejection fraction and fractional shortening obtained from M-mode views by a blinded echocardiography expert. For ejection fraction measurements, a long-or short-axis view of the heart was selected to obtain an M-mode registration in a line perpendicular to the left ventricular septum and posterior wall at the level of the mitral chordae tendinea.
Immunoblot analysis. Tissue extracts were prepared in Triton lysis buffer (20 mM Tris (pH 7.4), 1% Triton X-100, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 25 mM b-glycerophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and 10 mg ml À 1 of aprotinin and leupeptin), and for co-immunoprecipitation experiments, lysis buffer was supplemented with 0.3%
Chaps. Extracts (20-50 mg protein) and immunoprecipitates (prepared from 2-10 mg protein) were examined by immunoblot. For the immunoprecipitation assay, heart extracts were incubated with 4 mg of a specific antibody coupled to protein-G-Sepharose. After incubation overnight at 4°C with agitation, the captured proteins were centrifuged at 10,000g, the supernatants collected, and the beads washed four times in lysis buffer. Beads were boiled for 5 min 95°C in 10 ml sample buffer. Extracts and immunoprecipitates were examined by SDS-PAGE and blotted with antibodies to the following targets: p38g and p38d (refs 41,42) at 1 mg ml À 1 ; vinculin and Flag (Sigma); puromycin (Millipore clone 12D10); HA and Myc (Bethyl Laboratories, Inc.); ubiquitin (ThermoFisher); and phospho-p38, phospho-mTOR (Ser2481), mTOR, Myc-Tag, phospho-p70S6 kinase, p70S6 kinase, phospho-S6 (Ser 235/236), phospho-S6 (Ser 240/244), S6 ribosomal protein, phospho-FOXO1/3a, phospho-eEF2, eEF2, phospho-EIF4E, EIF4E, phospho-EIF4G, EIF4G, phospho-EIF4B, EIF4B, DEPTOR, phospho-MAPK/CDK substrate (PXSP or SPXR/K) (34B2), phospho-Threonine-Proline, Raptor, Rictor, Sin1, GbL, phospho-4EBP1, 4EBP1, phospho-AKT (Ser473) and AKT (Cell Signaling) all were used at 1:1,000. Immunocomplexes were detected by enhanced chemiluminescence (GE Healthcare Lifesciences). Full scans of all blots and gels are available as Supplementary Fig. 13 .
Cell lines and cell culture. HeLa and HEK-293T (American Type Culture Collection (ATCC), USA) cells and mouse embryonic fibroblasts (MEF) were cultured in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS; Sigma), glutamine (2 mM) and penicillin/streptomycin (100 mg ml À 1 ).
Lentivirus vector production and cell infection. Lentiviruses were produced by transient calcium phosphate co-transfection of HEK-293T cells was done with the pLKO mouse shRNA 1 DEPTOR (plasmid #21337 Addgene), pLKO mouse shRNA 2 DEPTOR (plasmid #21338 Addgene), together with pD8.9 and pVSV-G. Supernatants containing the LV particles were collected 48 and 72 h after removal of the calcium phosphate precipitate and were centrifuged at 700g at 4°C for 10 min and filtered through 0.45-mm filter units (Corning). Once filtered, the virus-containing medium was added (1:1 volume) to MEF culture medium. After incubation for 24 h at 37°C and 5% CO 2 , the medium was changed, and puromycin selection (3 mg ml À 1 puromycin) was initiated 48 h after infection. The selection medium was changed every 2 days during 1 week, and the cells were subsequently used for experiments.
Adeno-associated virus vector production and cell infection. The AAV shuttle and helper plasmids were transfected into HEK 293A cells by calcium-phosphate co-precipitation. A total of 840 mg plasmid DNA (mixed in an equimolar ratio) was used per Hyperflask (Corning) seeded with 1.2 Â 108 cells the day before. Seventy-two hours after transfection, the cells were collected by centrifugation and the cell pellet was resuspended in TMS (50 mM Tris HCl, 150 mM NaCl, 2 mM MgCl 2 ) on ice before digestion with DNase I and RNaseA (0.1 mg ml À 1 each; Roche) at 37°C for 60 min. Clarified supernatant containing the viral particles was obtained by iodixanol gradient centrifugation 44 . Gradient fractions containing virus were concentrated using Amicon UltraCel columns (Millipore) and stored at À 70°C (ref. 43) . AAV plasmids were cloned and propagated in the Stbl3 E. coli strain (Life Technologies). pRK5 FLAG human DEPTOR (plasmid #21334, Addgene), pCEFL Flag p38g D129A, pCMV Flag p38d F324S and pGIPZ mouse shRNA DEPTOR clone 1 (V3LMM_485571) were cloned into the pAcTnT AAV plasmid to generate pAAV-TnT-GFP-Luc, pAAV-TnT-p38g act , pAAV-TnT-p38d act , pAAV-TnT-Flag-DEPTOR and pAAV-TnT-shDeptor. These AAV plasmids were packaged into AAV-9 capsids with the use of pAdDF6 helper plasmids (providing the three adenoviral helper genes) and pAAV2/9 (providing rep and cap viral genes), obtained from PennVector. Shuttle vectors were generated by direct cloning (GeneScript) of synthesized NheI-SalI fragments into pAcTnT cut with the same restriction enzymes.
The AAV shuttle and helper plasmids were transfected into HEK 293A cells by calcium-phosphate co-precipitation. A total of 840 mg plasmid DNA (mixed in an equimolar ratio) was used per Hyperflask (Corning) seeded with 1.2 Â 10 8 cells the day before. Seventy-two hours after transfection, the cells were collected by centrifugation and the cell pellet was resuspended in TMS (50 mM Tris HCl, 150 mM NaCl, 2 mM MgCl 2 ) on ice before digestion with DNase I and RNaseA (0.1 mg ml À 1 each; Roche) at 37°C for 60 min. Clarified supernatant containing the viral particles was obtained by iodixanol gradient centrifugation 44 . Gradient fractions containing virus were concentrated using Amicon UltraCel columns (Millipore) and stored at À 70°C.
Standard curves were constructed using known copy numbers (10 5 -10 8 ) of the respective plasmid (pAAV-TnT-GFP-Luc, pAAV-TnT-p38g act , pAAV-TnTp38d act , pAAV-TNT-Flag-DEPTOR and pAAV-TNT-shDeptor) carrying the appropriate complementary DNA.
In vivo protein synthesis assay. For all in vivo measurements of protein synthesis, mice were injected intraperitoneally with 0.040 mmol g À 1 puromycin dissolved in 100 ml PBS. Exactly 30 min after injection, tissues were extracted and frozen in liquid N 2 for subsequent immunoblot analysis of protein-incorporated puromycin.
Measurement of in vitro protein synthesis by SUnSET assay. All the experiments were performed following the protocol described in ref. 45 with some modifications. MEFs were seeded in six-well plates with 10 6 cells per well in 1 ml complete DEMEM, and treated with 1 mg ml À 1 puromycin solution (Sigma) for 10 min at 37°C and 5% CO 2 ( ¼ pulse). The cells were washed twice with pre-warmed complete medium, resuspended in 1 ml of the same medium and incubated for 50 min at 37°C and 5% CO 2 ( ¼ chase). The cells were washed twice with cold PBS, and harvested. They were then washed once more by centrifugation at 4°C in cold PBS/0.1% BSA, and pellets were incubated in 30 ml of staining mix (mouse IgG2 anti-puromycin antibody (12D10) diluted 1/50 in PBS/BSA) for 30 min. The cells were washed twice with PBS/BSA and incubated in 30 ml of PE-labelled anti-mouse IgG (Invitrogen) diluted 1/100 in PBS/BSA. The cells were washed and resuspended in 200 ml PBS/BSA and analysed by FACS (fluorescence-activated cell sorting).
cDNA transfection-based experiments. Cells were plated at 60% confluence in DMEM/10%FBS 12-15 h before transfection. The cells were transfected using the calcium phosphate method 30 with the pRK5-based cDNA expression plasmids indicated in the figures. The culture medium was replaced 12 h after transfection with fresh complete medium, and cells were collected 48 h later. For DEPTOR degradation experiments in HEK 293T or HELA cells, the medium was changed after 24 h for medium lacking serum, and after a further 24 h, the cells were incubated in medium with 10% FBS or no FBS together with 10 mM cycloheximide. At the times indicated, the cells were collected and analysed by western blot. To block DEPTOR degradation induced by the constitutionally active p38g/d mutants, cells were preincubated with the proteasome inhibitor MG132 (Shelleckchem) at a final concentration of 10 mM.
The plasmids used in the different experiments were pRK5 myc Rat mTOR (plasmid #1861, Addgene); pRK5 FLAG human DEPTOR (plasmid #21334, Addgene); pRK5 FLAG human DEPTOR (13xS/T-A; plasmid #21702, Addgene); pRK5 FLAG DEPTOR (PDZ domain; plasmid #21701, Addgene); pRK5 FLAG DEPTOR (DEP domains; plasmid #21700, Addgene); pcDNA3-myc3-CUL1 (plasmid #19896, Addgene); pcDNA3-myc3-bTrCP (plasmid #20718, Addgene); HA-Ubiquitin (plasmid #18712); pcDNA3 HA human p38g and pcDNA3 HA human p38d, kindly provided by Roger Davis (University of Massachusetts Medical School, Worcester, USA); and pCEFL Flag p38g D129A and pCMV Flag p38d F324S , kindly provided by David Engelberg (The Hebrew University of Jerusalem, Israel).
In vitro kinase assay. One microgram of human GST-DEPTOR protein (H00064798, Novus Biologicals) was incubated for 30 min with 1 mg of active recombinant p38g, p38g or p38a kinases (provided by MRC Protein Phosphorylation and Ubiquitylation Unit, Dundee, UK) in the presence of 200 mM cold ATP. The reaction was stopped by adding SDS-containing sample buffer, and proteins were resolved by SDS-PAGE and visualized by staining with colloidal Coomassie Blue. The band containing GST-DEPTOR was excised and treated with DTT to reduce disulfide bonds and with iodoacetamide to derivatize cysteine residues. The protein was in-gel digested with trypsin, and the resulting peptides were extracted from the gel and analysed by nanoscale-microcapillary reversed phase liquid chromatography tandem mass spectrometry 46, 47 .
Flow cytometry cell size analysis. MEFs were trypsinized, washed and analysed by FACS to determine cell size based on the mean forward scattered light intensity.
Blood pressure measurement. Blood pressure in mice was measured using the noninvasive tail-cuff method 48 .
Statistical analysis. Differences between groups were examined for statistical significance by two-tailed Student's t-test, one-way or two-way analysis of variance coupled to the Bonferroni post test.
The rest of the materials and methods are found in the Supplementary Methods.
